HARBOR-AF Trial: First European Patient Dosed
Witfire Elite · Clinical Catalysts · Registry Analysis The ravulizumab ARTEMIS trial has been terminated at 555 patients. Read alone it is one failed…
Witfire Coverage
Category: Clinical Catalysts
PULSE-LHD Trial Enrols First U.S. Patients
Witfire Elite · Clinical Catalysts · Trial Design Audit Pulnovo says two U.S. participants have undergone PULSE-LHD procedures at Henry Ford. The registry estimates…
Ravulizumab ARTEMIS: 555 Patients, Six Terminations, and a Mechanism That Did Not Travel
Witfire Elite · Clinical Catalysts · Registry Analysis The ravulizumab ARTEMIS trial has been terminated at 555 patients. Read alone it is one failed…
OX40 Atopic Dermatitis: A Drug Class Ended in 175 Days and 8,185 Patients
Witfire Elite · Clinical Catalysts · Registry Analysis OX40 atopic dermatitis development is over. Two companies, two mechanisms, 175 days. The press releases said…